PubChem

Omadacycline is a new generation of aminomethylcyclotetracycline developed by Paratek Pharmaceuticals, which has a broad spectrum of activity against Gram-positive, Gram-negative and atypical bacteria.

Paratek Pharmaceuticals announced on October 2 that the FDA approved Seysara (sarecycline) for the treatment of moderate to severe acne in people over 9 years of age.

Sarecycline is a once-a-day, oral, narrow-spectrum tetracycline-derived antibiotic with anti-inflammatory properties that can be used as a potential treatment for moderate to severe acne in a community setting.

September 28, 2018, The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

Lung cancer is one of the most common malignant tumors and the first cause of death in malignant tumors in urban population in China. Non-small cell lung cancer accounts for 80% of lung cancer. EGFR is a protein that helps cells grow and divide. When it is mutated, it can cause cancer cells to form. EGFR mutations occur in 10% to 35% of non-small cell lung cancer worldwide.

The US FDA has approved Verastem's new anticancer drug Duvelisib (Copiktra) for the treatment of adults who have undergone at least two previous treatments, relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib also received accelerated approval for treatment of adult patients with relapsed or refractory follicular lymphoma.

Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults. In the same month, the EMA issued a positive opinion for galcanezumab for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY™] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine).

Doravirine has been used in trials studying the treatment of HIV-1, HIV-1 Infection, Renal Impairment, and Human Immunodeficiency Virus (HIV) Infection.

Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens [A38683].

2018.8.23, The U.S. Food and Drug Administration today approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I and II hereditary angioedema (HAE). HAE is a rare and serious genetic disease that affects people with low levels of and poorly functioning C1-INH proteins in the body. This results in recurrent, unpredictable episodes of severe swelling in different areas of the body, including the stomach, limbs, face and throat.